GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Synergy Pharmaceuticals Inc (FRA:S90) » Definitions » 3-Year EPS without NRI Growth Rate

Synergy Pharmaceuticals (FRA:S90) 3-Year EPS without NRI Growth Rate : 0.70% (As of Sep. 2018)


View and export this data going back to 2012. Start your Free Trial

What is Synergy Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Synergy Pharmaceuticals's EPS without NRI for the three months ended in Sep. 2018 was €-0.12.

During the past 3 years, the average EPS without NRI Growth Rate was 0.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -11.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 12 years, the highest 3-Year average EPS without NRI Growth Rate of Synergy Pharmaceuticals was 0.70% per year. The lowest was 0.00% per year. And the median was -29.10% per year.


Competitive Comparison of Synergy Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Synergy Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Synergy Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Synergy Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Synergy Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Synergy Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Synergy Pharmaceuticals  (FRA:S90) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Synergy Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Synergy Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Synergy Pharmaceuticals (FRA:S90) Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Avenue, Suite 2012, New York, NY, USA, 10170
Synergy Pharmaceuticals Inc functions in the healthcare sector based in the United States. It focusses on developing therapies to combat gastrointestinal diseases. The company's basic ingredient is the uroguanylin analog, which it employs in its products candidates such as plecanatide and dolcanatide. Plecanatide is a once-daily tablet, which addresses chronic idiopathic constipation and the irritable bowel syndrome. Dolcanatide is meant to cure inflammatory bowel disease by aiding the process of digestive breakdown.

Synergy Pharmaceuticals (FRA:S90) Headlines

No Headlines